AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Airbus Joins Air India A320 Altitude Drop Probe 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
ADNOC Gas Targets Up to $4B Profit in 2026 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
